Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized mutation tracking could spot relapse sooner in bone marrow cancer patients

NCT ID NCT02872662

Knowledge-focused Sponsor: Nordic MDS Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising mutation levels could signal a relapse before it becomes obvious, potentially allowing earlier treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a way to catch relapse earlier in MDS patients after transplant, potentially improving outcomes.
What could go wrong
This is an observational study, not a treatment trial. It may not change patient outcomes directly, and the methods may not be widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

308 people

The number who actually took part.

Started

Aug 2016

Finished

Nov 2021

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

200 consecutive MDS patients undergoing allogeneic SCT

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. MDS with allo SCT to be performed 2. One or more mutations identified 3. Written informed consent Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bilateral multicystic dysplastic kidney myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm spondylocarpotarsal synostosis syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MDS MRD SCT

Contacts and locations

Locations

  • Department of Hematology and Coagulation, Sahlgrenska University hospital

    Gothenburg, 413 45, Sweden

  • Department of Hematology, Aarhus University Hospital

    Aarhus, 8000, Denmark

  • Department of Hematology, Akademiska University Hospital

    Uppsala, 751 85, Sweden

  • Department of Hematology, Karolinska University Hospital

    Stockholm, Sweden

  • Department of Hematology, Lund University Hospital

    Lund, 221 85, Sweden

  • Department of Hematology, Rigshospitalet Univsersity Hospital

    Copenhagen, Denmark

  • Department of Hematology, Rikshospitalet University Hospital

    Oslo, 0027, Norway

  • Department of Medcine, Haukeland University Hospital

    Bergen, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.